2026年第一季度营收同比增长79%至2.16亿美元,主要得益于分子分析服务85%的增长;毛利率从47%提升至65%。 每股收益(EPS)为0美元,超出市场预期的每股亏损0.12美元100%;实现连续第四个季度调整后EBITDA为正,达到2600万美元,并产生2350万美元自由现金流。 尽管财报表现强劲,但盘后股价仍大跌15.58%至16.15美元,年初至今累计下跌46%,目前交投于52周低点附近 ...
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through ...
立足香港,放眼世界。新浪财经全球资本峰会金曜奖投票启动!挖掘最具价值的资本力量,你的一票,至关重要 点击投票 周四,Conexeu Sciences(CNXU.US)登陆美股市场,开盘股价跌超3.6%,报13.01美元。IPO价格为13.5美元。Conexeu Sciences是一家美国早期医疗科技公司,专注于开发基于胶原蛋白的再生医学材料,主要用于伤口修复、牙科软组织修复以及医美领域。公司总部位 ...
BEIJING, May 18 (Xinhua) -- General Secretary of the Communist Party of China (CPC) Central Committee Xi Jinping has urged accelerated efforts in building up China's knowledge system in philosophy and ...
Chinese President Xi Jinping has stressed accelerating the building of a Chinese intellectual system in philosophy and social ...
WASHINGTON — The National Academies of Sciences, Engineering, and Medicine’s New Voices in Sciences, Engineering, and Medicine program has announced its 2026-2028 cohort of members, a group of 20 ...
Uncertainty is a defining feature of the modern world—from climate change and pandemics to financial instability, cybersecurity threats, and disruptive technologies. In a new article published in Risk ...
Awakn Life Sciences (AWKN) (ISIN: CA05455W1086)股票专题,提供今日Awakn Life Sciences(AWKN) (ISIN: CA05455W1086)股票最新股价查询,实时市场行情,走势图表,及Awakn Life Sciences Corp(AWKN) (ISIN: CA05455W1086)股票的专业技术分析,投资者论坛,历史交易数据,最新 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果